Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 371

1.

Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study.

Kivitz AJ, Nash P, Tahir H, Everding A, Mann H, Kaszuba A, Pellet P, Widmer A, Pricop L, Abrams K.

Rheumatol Ther. 2019 Jun 21. doi: 10.1007/s40744-019-0163-5. [Epub ahead of print]

2.

Psychometric Evaluation of the MOBID Dementia Pain Scale in U.S. Nursing Homes.

Herr K, Sefcik JS, Neradilek MB, Hilgeman MM, Nash P, Ersek M.

Pain Manag Nurs. 2019 Jun;20(3):253-260. doi: 10.1016/j.pmn.2018.11.062. Epub 2019 May 10.

PMID:
31085096
3.

Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib.

Bird P, Hall S, Nash P, Connell CA, Kwok K, Witcombe D, Thirunavukkarasu K.

RMD Open. 2019 Feb 23;5(1):e000742. doi: 10.1136/rmdopen-2018-000742. eCollection 2019.

4.

2018 update of the APLAR recommendations for treatment of rheumatoid arthritis.

Lau CS, Chia F, Dans L, Harrison A, Hsieh TY, Jain R, Jung SM, Kishimoto M, Kumar A, Leong KP, Li Z, Lichauco JJ, Louthrenoo W, Luo SF, Mu R, Nash P, Ng CT, Suryana B, Wijaya LK, Yeap SS.

Int J Rheum Dis. 2019 Mar;22(3):357-375. doi: 10.1111/1756-185X.13513. Epub 2019 Feb 27.

PMID:
30809944
5.

Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis.

Strand V, McInnes I, Mease P, Nash P, Thom H, Kalyvas C, Hunger M, Gandhi K, Pricop L, Jugl S, Choy E.

J Comp Eff Res. 2019 May;8(7):497-510. doi: 10.2217/cer-2018-0141. Epub 2019 Feb 26.

6.

Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.

van der Heijde D, Strand V, Tanaka Y, Keystone E, Kremer J, Zerbini CAF, Cardiel MH, Cohen S, Nash P, Song YW, Tegzová D, Gruben D, Wallenstein G, Connell CA, Fleischmann R; ORAL Scan Investigators.

Arthritis Rheumatol. 2019 Jun;71(6):878-891. doi: 10.1002/art.40803. Epub 2019 Apr 24.

7.

Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks.

Kavanaugh A, Marzo-Ortega H, Vender R, Wei CC, Birt J, Adams DH, Benichou O, Lin CY, Nash P.

Clin Exp Rheumatol. 2019 Jul-Aug;37(4):566-574. Epub 2018 Nov 19.

8.

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.

Coates LC, Gladman DD, Nash P, FitzGerald O, Kavanaugh A, Kvien TK, Gossec L, Strand V, Rasouliyan L, Pricop L, Ding K, Jugl SM, Gaillez C; FUTURE 2 study group.

Arthritis Res Ther. 2018 Dec 7;20(1):272. doi: 10.1186/s13075-018-1773-y.

9.

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies.

Nash P, Coates LC, Fleischmann R, Papp KA, Gomez-Reino JJ, Kanik KS, Wang C, Wu J, Menon S, Hendrikx T, Ports WC.

Rheumatol Ther. 2018 Dec;5(2):567-582. doi: 10.1007/s40744-018-0131-5. Epub 2018 Nov 9.

10.

Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison.

Maksymowych WP, Strand V, Nash P, Yazici Y, Thom H, Hunger M, Kalyvas C, Gandhi KK, Porter B, Jugl SM.

Eur J Rheumatol. 2018 Dec;5(4):216-223. doi: 10.5152/eurjrheum.2018.18162. Epub 2018 Oct 30.

11.

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.

Helliwell P, Coates LC, FitzGerald O, Nash P, Soriano ER, Elaine Husni M, Hsu MA, Kanik KS, Hendrikx T, Wu J, Kudlacz E.

Arthritis Res Ther. 2018 Oct 29;20(1):242. doi: 10.1186/s13075-018-1739-0.

12.

Irritant Contact Dermatitis.

Bains SN, Nash P, Fonacier L.

Clin Rev Allergy Immunol. 2019 Feb;56(1):99-109. doi: 10.1007/s12016-018-8713-0. Review.

PMID:
30293200
13.

Developing a Pain Intensity Measure for Persons with Dementia: Initial Construction and Testing.

Ersek M, Herr K, Hilgeman MM, Neradilek MB, Polissar N, Cook KF, Nash P, Snow AL, McDarby M, Nelson FX.

Pain Med. 2018 Oct 3. doi: 10.1093/pm/pny180. [Epub ahead of print]

PMID:
30285252
15.

Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis.

McInnes IB, Nash P, Ritchlin C, Choy EH, Kanters S, Thom H, Gandhi K, Pricop L, Jugl SM.

J Comp Eff Res. 2018 Nov;7(11):1107-1123. doi: 10.2217/cer-2018-0075. Epub 2018 Sep 19.

16.

Psychometric Evaluation of a Pain Intensity Measure for Persons with Dementia.

Ersek M, Neradilek MB, Herr K, Hilgeman MM, Nash P, Polissar N, Nelson FX.

Pain Med. 2018 Sep 10. doi: 10.1093/pm/pny166. [Epub ahead of print]

PMID:
30204895
17.

Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials.

Mease P, Roussou E, Burmester GR, Goupille P, Gottlieb A, Moriarty SR, Benichou O, Adams DH, Xu W, Nash P.

Arthritis Care Res (Hoboken). 2019 Mar;71(3):367-378. doi: 10.1002/acr.23738. Epub 2019 Feb 12.

18.

Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2.

Genovese MC, Combe B, Kremer JM, Tsai TF, Behrens F, Adams DH, Lee C, Kerr L, Nash P.

Rheumatology (Oxford). 2018 Nov 1;57(11):2001-2011. doi: 10.1093/rheumatology/key182.

19.

Adapting the Advocate Health Care Taxonomy of Chaplaincy for a Pediatric Hospital Context: A Pilot Study.

Nash P, Roberts E, Nash S, Darby K, Parwaz AA.

J Health Care Chaplain. 2019 Apr-Jun;25(2):61-75. doi: 10.1080/08854726.2018.1473911. Epub 2018 Jul 27.

PMID:
30052490
20.

Country Doc.

Nash P.

Chest. 2018 Jul;154(1):220. doi: 10.1016/j.chest.2017.12.022. No abstract available.

PMID:
30044732
21.

CQESTR-Simulated Response of Soil Organic Carbon to Management, Yield, and Climate Change in the Northern Great Plains Region.

Nash PR, Gollany HT, Sainju UM.

J Environ Qual. 2018 Jul;47(4):674-683. doi: 10.2134/jeq2017.07.0273.

PMID:
30025061
22.

Simulated Soil Organic Carbon Responses to Crop Rotation, Tillage, and Climate Change in North Dakota.

Nash PR, Gollany HT, Liebig MA, Halvorson JJ, Archer DW, Tanaka DL.

J Environ Qual. 2018 Jul;47(4):654-662. doi: 10.2134/jeq2017.04.0161.

PMID:
30025045
23.

Simulated Soil Organic Carbon Response to Tillage, Yield, and Climate Change in the Southeastern Coastal Plains.

Nash PR, Gollany HT, Novak JM, Bauer PJ, Hunt PG, Karlen DL.

J Environ Qual. 2018 Jul;47(4):663-673. doi: 10.2134/jeq2017.05.0190.

PMID:
30025032
24.

Simulated Soil Organic Carbon Changes in Maryland Are Affected by Tillage, Climate Change, and Crop Yield.

Cavigelli MA, Nash PR, Gollany HT, Rasmann C, Polumsky RW, Le AN, Conklin AE.

J Environ Qual. 2018 Jul;47(4):588-595. doi: 10.2134/jeq2017.07.0291.

PMID:
30025031
25.

Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population.

Hall S, Nash P, Rischmueller M, Bossingham D, Bird P, Cook N, Witcombe D, Soma K, Kwok K, Thirunavukkarasu K.

Rheumatol Ther. 2018 Dec;5(2):383-401. doi: 10.1007/s40744-018-0118-2. Epub 2018 Jun 11.

26.

Psoriatic arthritis: novel targets add to a therapeutic renaissance.

Nash P.

Lancet. 2018 Jun 2;391(10136):2187-2189. doi: 10.1016/S0140-6736(18)31217-0. Epub 2018 Jun 1. No abstract available.

PMID:
29893210
27.

Correction to: Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.

Nash P, McInnes IB, Mease PJ, Thom H, Hunger M, Karabis A, Gandhi K, Mpofu S, Jugl SM.

Rheumatol Ther. 2018 Dec;5(2):595. doi: 10.1007/s40744-018-0117-3.

28.

Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors.

Tymms K, Littlejohn G, Griffiths H, de Jager J, Bird P, Joshua F, Nash P, Handel M, McManus H, Butcher BE, Youssef P.

Clin Rheumatol. 2018 Jun;37(6):1617-1623. doi: 10.1007/s10067-018-4105-3. Epub 2018 Apr 18.

PMID:
29667098
29.

Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial.

Genovese MC, Pacheco-Tena C, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente RM, Nash P, Simon-Campos JA, Box J, Legerton CW 3rd, Nasonov E, Durez P, Elegbe A, Wong R, Li X, Banerjee S, Alten R.

J Rheumatol. 2018 Aug;45(8):1085-1092. doi: 10.3899/jrheum.170344. Epub 2018 Apr 15.

30.

Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.

Nash P, McInnes IB, Mease PJ, Thom H, Hunger M, Karabis A, Gandhi K, Mpofu S, Jugl SM.

Rheumatol Ther. 2018 Jun;5(1):99-122. doi: 10.1007/s40744-018-0106-6. Epub 2018 Mar 31. Erratum in: Rheumatol Ther. 2018 Dec;5(2):595.

31.

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3).

Nash P, Mease PJ, McInnes IB, Rahman P, Ritchlin CT, Blanco R, Dokoupilova E, Andersson M, Kajekar R, Mpofu S, Pricop L; FUTURE 3 study group.

Arthritis Res Ther. 2018 Mar 15;20(1):47. doi: 10.1186/s13075-018-1551-x.

32.

Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).

Nash P, Ohson K, Walsh J, Delev N, Nguyen D, Teng L, Gómez-Reino JJ, Aelion JA; ACTIVE investigators.

Ann Rheum Dis. 2018 May;77(5):690-698. doi: 10.1136/annrheumdis-2017-211568. Epub 2018 Jan 17.

33.

Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial.

Bandyopadhyay S, Connolly SE, Jabado O, Ye J, Kelly S, Maldonado MA, Westhovens R, Nash P, Merrill JT, Townsend RM.

Lupus Sci Med. 2017 Jul 28;4(1):e000206. doi: 10.1136/lupus-2017-000206. eCollection 2017.

34.

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis.

Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJJ, Bertheussen H, Boehncke WH, Callis Duffin K, Campbell W, de Wit M, Gladman D, Gottlieb A, James J, Kavanaugh A, Kristensen LE, Kvien TK, Luger T, McHugh N, Mease P, Nash P, Ogdie A, Rosen CF, Strand V, Tillett W, Veale DJ, Helliwell PS.

Arthritis Rheumatol. 2018 Mar;70(3):345-355. doi: 10.1002/art.40391. Epub 2018 Feb 6.

35.

The Role of Food Antioxidants, Benefits of Functional Foods, and Influence of Feeding Habits on the Health of the Older Person: An Overview.

Wilson DW, Nash P, Buttar HS, Griffiths K, Singh R, De Meester F, Horiuchi R, Takahashi T.

Antioxidants (Basel). 2017 Oct 28;6(4). pii: E81. doi: 10.3390/antiox6040081. Review.

36.

Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.

Charles-Schoeman C, van der Heijde D, Burmester GR, Nash P, Zerbini CAF, Connell CA, Fan H, Kwok K, Bananis E, Fleischmann R.

J Rheumatol. 2018 Feb;45(2):177-187. doi: 10.3899/jrheum.170486. Epub 2017 Nov 15.

37.

Experimental formation enthalpies for intermetallic phases and other inorganic compounds.

Kim G, Meschel SV, Nash P, Chen W.

Sci Data. 2017 Oct 24;4:170162. doi: 10.1038/sdata.2017.162.

38.

Remission in psoriatic arthritis-where are we now?

Coates LC, Conaghan PG, D'Agostino MA, De Wit M, FitzGerald O, Kvien TK, Lories R, Mease P, Nash P, Schett G, Soriano ER, Emery P.

Rheumatology (Oxford). 2018 Aug 1;57(8):1321-1331. doi: 10.1093/rheumatology/kex344.

39.

Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab.

Burmester GR, Kaeley GS, Kavanaugh AF, Gabay C, MacCarter DK, Nash P, Takeuchi T, Goss SL, Rodila R, Chen K, Kupper H, Kalabic J.

RMD Open. 2017 Sep 17;3(2):e000465. doi: 10.1136/rmdopen-2017-000465. eCollection 2017.

40.

Dementia-friendly public toilets.

Tales A, Burholt V, Nash P, Bichard JA, Clayton-Turner A; 16 signatories.

Lancet. 2017 Aug 5;390(10094):552-553. doi: 10.1016/S0140-6736(17)31813-5. No abstract available.

PMID:
28792390
41.

Impact of intrapatient variability (IPV) in tacrolimus trough levels on long-term renal transplant function: multicentre collaborative retrospective cohort study protocol.

Goldsmith PM, Bottomley MJ, Okechukwu O, Ross VC, Ghita R, Wandless D, Falconer SJ, Papachristos S, Nash P, Androshchuk V, Clancy M; Transplant Audit Collaborative.

BMJ Open. 2017 Jul 28;7(7):e016144. doi: 10.1136/bmjopen-2017-016144.

42.

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.

Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M; SPIRIT-P2 Study Group.

Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24.

PMID:
28551073
43.

A Machine Learning Approach to Evaluating Illness-Induced Religious Struggle.

Glauser J, Connolly B, Nash P, Grossoehme DH.

Biomed Inform Insights. 2017 Feb 8;9:1178222616686067. doi: 10.1177/1178222616686067. eCollection 2017.

44.

Patient and Healthcare Professionals Preference for Brenzys vs. Enbrel Autoinjector for Rheumatoid Arthritis: A Randomized Crossover Simulated-Use Study.

Egeth M, Soosaar J, Nash P, Choquette D, Infante R, Ramey DR, Sahakian S, Lai A, Kim JJ, Wu D.

Adv Ther. 2017 May;34(5):1157-1172. doi: 10.1007/s12325-017-0523-x. Epub 2017 Apr 17.

45.

Advances in rheumatoid arthritis.

Jones G, Nash P, Hall S.

Med J Aust. 2017 Mar 20;206(5):221-224. Review.

PMID:
28301793
46.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6. Review.

47.

A Sensitive in Vitro High-Throughput Screen To Identify Pan-filoviral Replication Inhibitors Targeting the VP35-NP Interface.

Liu G, Nash PJ, Johnson B, Pietzsch C, Ilagan MX, Bukreyev A, Basler CF, Bowlin TL, Moir DT, Leung DW, Amarasinghe GK.

ACS Infect Dis. 2017 Mar 10;3(3):190-198. doi: 10.1021/acsinfecdis.6b00209. Epub 2017 Feb 9.

48.

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.

Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J.

Ann Rheum Dis. 2017 Jul;76(7):1253-1262. doi: 10.1136/annrheumdis-2016-210457. Epub 2017 Jan 31.

49.

Delivering high quality hip fracture rehabilitation: the perspective of occupational and physical therapy practitioners.

Leland NE, Lepore M, Wong C, Chang SH, Freeman L, Crum K, Gillies H, Nash P.

Disabil Rehabil. 2018 Mar;40(6):646-654. doi: 10.1080/09638288.2016.1273973. Epub 2017 Jan 23.

50.

Valuing older people: time for a global campaign to combat ageism.

Officer A, Schneiders ML, Wu D, Nash P, Thiyagarajan JA, Beard JR.

Bull World Health Organ. 2016 Oct 1;94(10):710-710A. No abstract available.

Supplemental Content

Support Center